Scientific Advisory Board

To augment our science team’s capabilities, we have created a Scientific Advisory Board. These individuals have deep experience in a variety of areas.

Scientific Advisory Board

Leo Furcht, M.D.

Dr. Furcht is Allen-Pardee Professor and Endowed Chair of the Department of Laboratory Medicine and Pathology at the University of Minnesota. He is also chairman of the Board of Directors, University of Minnesota Physicians. Dr. Furcht’s research interests include tumor cell behavior, extracellular matrix protein expression, integrins, and cell adhesion molecules.

Edward Greeno, M.D.

Dr. Greeno is Medical Director of the Hematology/Oncology Clinic at the University of Minnesota and an Associate Professor at the University of Minnesota Medical School. He has been listed as one of the Best Doctors in America for a number for years.

Sara Hurvitz, M.D.

Dr. Hurvitz is Director, Breast Cancer Clinical Research Programs at the Geffen School of Medicine at UCLA and an Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA.  She is also the Co-Director of the Santa Monica-UCLA Outpatient Hematology/Oncology Practice and Medical Director of the Jonsson Comprehensive Cancer Center Clinical Research Unit. Dr. Hurvitz is interested in designing and implementing phase I and II (translational) breast cancer clinical trials. Dr. Hurvitz is also interested in studying the gene expression patterns in a variety of breast cancer populations, and evaluating these patterns to detect new subtypes of breast cancer that may be more accurately targeted by novel therapies.

Carol Lange, Ph.D.

Dr. Lange is Professor of Medicine and Pharmacology at the University of Minnesota. She is also Endowed Chair of the Tickle Family Land Grant in Breast Cancer Research and Director of the Women’s Cancer Program at the University of Minnesota. Dr. Lange studies the molecular biology of breast cancer. Her laboratory is focused on the study of cross-talk between peptide growth factors and steroid hormone receptors in human breast cancer cells, with the goal of developing better strategies for the treatment of breast and other hormonally influenced and/or epithelial cell-derived cancers.

Benita Katzenellenbogen, Ph.D.

Dr. Katzenellenbogen is the Swanlund Professor of Molecular and Integrative Physiology and the Swanlund Professor of Cell and Developmental Biology at the University of Illinois School of Molecular and Cellular Biology. Her research interests include regulation of gene expression, signal transduction, and cell proliferation and phenotypic properties by hormones and growth factors as well as biomarker discovery and cellular changes underlying resistance to therapeutic agents in breast cancer.

Ron McGlennen, M.D.

Dr. McGlennen is President and Medical Director of Access Genetics, a molecular diagnostics company he cofounded in 2001. Previously he was an Associate Professor at the University of Minnesota. He also serves as Celcuity’s Medical Director.

John Katzenellengogen, Ph.D.

Dr. Katzenellenbogen is Research Professor of Chemistry at the University of Illinois, an Affiliate of the Beckman Institute and Department of Bioengineering, and a Fellow of the American Academy of Arts and Sciences. His research has focused on aspects of the structure, function, and the use of steroid receptors, and includes biochemical and biophysical studies on the dynamics of the estrogen receptors and their interaction with coregulator proteins.